Abstract
Apatinib is a kind of antiangiogenesis drug of small molecular tyrosine kinase inhibitor, which can strongly against tumor angiogenesis by inhibiting vascular endothelial growth factor receptor 2 with highly selectivity. Apatinib can block cell cycle and reverse drug resistance. Clinical studies have shown that Apatinib is effective for many malignant tumors, including non-small cell lung cancer, breast cancer and gastric cancer, which has encouraging objective response rate and survival benefit. Apatinib also has good safety and tolerance. Key words: Neoplasms; Neovascularization, pathologic; Apatinib; Vascular endothelial growth factor receptor-2; Molecular targeted therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
